Abstract: The 2024 CSCO Breast Cancer Diagnosis and Treatment Guidelines have synthesized key international and domestic research advancements in 2023, considering drug accessibility and medical insurance and incorporating a measure of Chinese experts consensus to update diagnosis and treatment recommendations. These guidelines recommend best practices for treatment of different types of breast cancer, including hormone receptor-positive (HR+), HER2-positive and triple-negative breast cancer. Moreover, the guidelines include diagnosis and treatment recommendations for HER2-low advanced breast cancer and provision of standardized and precise treatment options to patients with different cancer types and stratification. This study aimed to interpret the key updated points for advanced breast cancer treatment.